Cancer Cell Research (Online ISSN: 2161-2609)

Cancer Cell Research 2019 6(22) 569-572; published online  18 May 2019

Abstract: Pancreatic cancer is a very malignant tumor, and its incidence is increasing year by year, which seriously threatens people's health. At present, in addition to surgical treatment, molecular pathway-related targeted therapy is becoming a hot topic for treatment. This article will combine the relevant literatures to review the related molecular pathways of pancreatic cancer, and provide more theoretical basis for targeted therapy.

Cancer Cell Research 2019 6(22) 573-577; published online  18 May 2019

Abstract: To assess the incidence of ASXL2 mutations in acute myeloid leukemia (AML) patients with RUNX1-RUNX1T1 fusion gene and the association with clinical features and prognosis, amplicon-targeted next generation sequencing of ASXL2, ASXL1, and KIT genes were carried out in 83 AML patients with RUNX1-RUNXT1. ASXL2 and ASXL1 mutations of cases were 13 (15.66%) and 11 (13.25%), respectively. One patient has two genes mutation. The median white blood cell count of the 13 patients with ASXL2 mutations was 20.1 (3.4-139.03) × 109/L, which was higher than that of patients without ASXL2 mutations (20.1 vs. 13.14, P = 0.025). There was no significant difference in peripheral blood hemoglobin level, platelet count and bone marrow blast count between the two groups (P>0.05). Overall survival and event-free survival between the two groups were also no significant difference (P>0.05). These data suggest that ASXL2 mutations are associated with high level of white blood cell counts in AML patients with RUNX1-RUNXT1.

Cancer Cell Research 2019 6(22) 578-580; published online  21 April 2019

Abstract: To investigate characteristics of diagnosis and treatment of retroperitoneal primitive neuroectodermal tumors. The clinical data of 8 patients with retroperitoneal primitive neuroectodermal tumors admitted to the Affiliated Hospital of Qingdao University from May 2011 to September 2017 were retrospectively analyzed. All patients were confirmed by pathology as primitive neuroectodermal tumors. 2 cases underwent needle biopsy before surgery, 3 cases were given palliative resection, 5 cases accepted complete resection of the tumor, and 4 cases were combined organ resection. The retroperitoneal primitive neuroectodermal tumor is a highly malignancy and is difficult to diagnose before operation. The main treatment is surgery-based comprehensive treatment, and the prognosis of this disease is poor.

Cancer Cell Research 2019 6(22) 581-589; published online  28 May 2019

Abstract: The aim of this study was to investigate the injury of human coronary artery endothelial cells (HCAECs) induced by high oxidized low density lipoprotein (ox-LDL) and to examine the protective effect of hydroxysafflor yellow A (HSYA) on HCAECs injury. It was found that in the high ox-LDL group the content of NO, the expression of endothelial nitric oxide synthase (eNOS) mRNA and protein were decreased. The expression of LDH, lectin-like low-density lipoprotein receptor 1 (LOX-1) mRNA and LOX-1 protein were up-regulated. The number of apoptotic cells were significantly increased after deal with high ox-LDL compared with the control group. Furthermore, in the high ox-LDL+HSYA group, the cell survival rate, the release of NO and the expression of eNOS mRNA and eNOS protein were increased. The secretion of LDH and the expression of LOX-1 at the level of mRNA and protein were down-regulated. The number of apoptosis were significantly reduced after combined with HSYA compared with the high ox-LDL group. Therefore, high ox-LDL had an obvious damage to HCAECs. The HSYA inhibited the high ox-LDL-induced HCAECs injury and protected and promoted the cell repaired, possibly by up-regulating the eNOS gene and protein expression, increasing NO release, inhibiting LDH release and down-regulating LOX-1 mRNA and protein expression to achieve the effect. The treatment and secondary prevention of coronary heart disease, as well as the recovery of patients undergoing postoperative percutaneous coronary intervention (PCI), will benefit to a large extent.

Cancer Cell Research 2019 6(22) 602-606; published online  28 May 2019

Abstract: To investigate the relationship between EBV infection and the occurrence and development of chronic lymphoblastic leukemia (CLL), and to provide a reliable basis for revealing the close relationship between EBV infection and CLL. Fluorescence quantitative polymerase chain reaction (FQ-PCR) was used to detect the copy numbers of EBV-DNA from the bone marrow of 80 CLL patients. 40 healthy persons were control group and 40 cases for clinical follow-up. The results showed that the EBV positive rates (EBV+) of CLL patients and healthy controls were 25% (20/80) and 7.5% (3/40) respectively. Chromosome analysis showed that the rate of EBV+ in CLL patients with chromosome abnormalities was 18.75% (3/16), while the rate of EBV- was 81.25% (13/16), and no significant difference was observed between chromosome abnormality and EBV infection (2=0.21, p>0.05). Clinical follow-up showed that the relapse rate mortality rate of EBV+ and EBV- groups within 5 years were 55.6% (10/18), 28.6% (12/42) and 44.4% (8/18), 4.7% (2/42), respectively (p<0.05). ML-EBV+ had higher relapse and mortality rates compared with ML-EBV-. 6 patients with EBV-positive CLL progressed to diffuse large B-cell lymphoma (DLBCL). EBV infection may be related to the occurrence and development of CLL. EBV infection is not conducive to the prognosis of CLL. And EBV may participate in the transformation of CLL to DLBCL.